Nolato AB (publ) (LON:0OA9)
London · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 1.06B -12.0% |
| Revenue (ttm) | 732.94M -2.1% |
| Net Income | 55.68M -3.0% |
| EPS | 0.21 -3.3% |
| Shares Out | n/a |
| PE Ratio | 19.01 |
| Forward PE | 15.49 |
| Dividend | 0.14 (3.57%) |
| Ex-Dividend Date | May 7, 2026 |
| Volume | 4,686 |
| Open | 49.05 |
| Previous Close | 49.05 |
| Day's Range | 49.05 - 50.50 |
| 52-Week Range | 45.82 - 64.65 |
| Beta | 0.74 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 17, 2026 |
About Nolato AB
Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally. It operates through the Medical Solutions and Engineered Solutions segments. The company offers catheter balloons; breathing bags; non-conductive sealing and damping silicone products; primary plastic packaging for medicines; and crimp and dropper bottles. It also provides thermal heating pads, gap fillers, and paste under the Compatherm brand; Autolys M products, deep well plates, micro... [Read more]
Financial Performance
In 2025, Nolato AB's revenue was 9.46 billion, a decrease of -2.09% compared to the previous year's 9.66 billion. Earnings were 777.00 million, an increase of 18.09%.
Financial numbers in SEK Financial StatementsNews
Nolato AB Earnings Call Transcript: Q2 2026
Q2 2026 saw 4% sales growth and strong cash flow, despite margin pressure from higher raw material costs and startup expenses. Medical Solutions led growth, while Engineered Solutions excelled in materials. Margin recovery and continued expansion are expected.
Nolato AB Quarterly report: Q2 2026
Nolato AB has published its Q2 2026 quarterly earnings report on July 17, 2026.
Nolato AB Slides: Q2 2026
Nolato AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 17, 2026.
Nolato AB Earnings Call Transcript: Q1 2026
Q1 2026 saw 3% organic sales growth and stable margins despite currency and input cost headwinds. Medical Solutions led growth, while Engineered Solutions benefited from strong materials and electronics demand. Margin normalization is expected by Q3 as cost increases are passed on.
Nolato AB Quarterly report: Q1 2026
Nolato AB has published its Q1 2026 quarterly earnings report on May 6, 2026.
Nolato AB Slides: Q1 2026
Nolato AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Nolato AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 2% sales growth adjusted for currency, with Medical Solutions up 5% and Engineered Solutions down 1%. Margins improved year-over-year, but were impacted by currency headwinds and higher material costs. CapEx and M&A activity remain elevated.
Nolato AB Annual report: Q4 2025
Nolato AB has published its Q4 2025 annual report on February 5, 2026.
Nolato AB Quarterly report: Q4 2025
Nolato AB has published its Q4 2025 quarterly earnings report on February 5, 2026.
Nolato AB Slides: Q4 2025
Nolato AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 5, 2026.
Nolato AB Earnings Call Transcript: Q3 2025
Organic growth and margin improvements drove a 20% EBITDA increase, with strong performance in both Medical and Engineered Solutions. Ongoing expansions and investments support future growth, while the materials business faces continued pressure from the automotive sector.
Nolato AB Quarterly report: Q3 2025
Nolato AB has published its Q3 2025 quarterly earnings report on October 28, 2025.
Nolato AB Slides: Q3 2025
Nolato AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 28, 2025.